FDA Approves New Treatment for Early Alzheimer’s
The Food and Drug Administration on Friday approved a new Alzheimer’s drug that may modestly slow the pace of cognitive decline early in the disease, but also carries risks of swelling and bleeding in the brain. The approval of the drug, lecanemab, to be marketed as Leqembi, is likely to generate considerable interest from patients…